Association between the use of statins and periodontal status: a review

Background: Statins are drugs used for the treatment of dyslipidemia. However, statins have multiple actions, including anti-inflammatory and immunomodulatory effects, as well as the ability to stimulate new bone formation. Such features could be beneficial for periodontal pathology therapy. Methods: A literature review was conducted using filtered electronic databases (Cochrane and Trip) and unfiltered databases (Medline/PubMed, Scielo and Google Scholar). The articles chosen were controlled and randomized clinical trials that performed local delivery of statins to humans and assessed the effects of immunomodulation and bone regeneration on periodontal disease between 2010 and 2017. All of the studies were blind or double-blind and were written in English. Results: The inclusion criteria were applied to a total of 79 identified articles, and 10 studies were ultimately chosen. The results show that an injected dose of statins or the local delivery of atorvastatin (ATV) leads to a significant improvement in clinical and radiographic periodontal parameters. Moreover, rosuvastatin (RSV) induced stronger beneficial effects when administered systemically, whereas ATV and simvastatin (SMV) had better results following topical delivery. Conclusions: Statins can affect periodontal status, increasing the gain in clinical attachment and decreasing gingival bleeding, probing depth and the magnitude of bone defects. For this reason, statins represent an excellent support measure for conventional periodontal therapy. Specifically, positive effects are seen for local delivery of statins as an adjunct treatment to scaling and root planing (SRP) at doses of 1.2 to 2%. Statins could be administered through topical delivery via direct injection in the periodontal pocket or by brushing with medicated dentifrices. More studies with appropriate designs should evaluate the short and long term clinical benefit of statins inpatients with periodontal pathology. These studies should determine the appropriate dose, timing side effects and ideal vehicles for delivery.

[1]  A. Pradeep,et al.  Subgingivally delivered 1.2% atorvastatin in the treatment of chronic periodontitis among smokers: a randomized, controlled clinical trial , 2017, Journal of investigative and clinical dentistry.

[2]  S. Singhal,et al.  1.2% Rosuvastatin Versus 1.2% Atorvastatin Gel Local Drug Delivery and Redelivery in Treatment of Intrabony Defects in Chronic Periodontitis: A Randomized Placebo-Controlled Clinical Trial. , 2016, Journal of periodontology.

[3]  A. Pradeep,et al.  Efficacy of locally delivered 1.2% rosuvastatin gel to non-surgical treatment of patients with chronic periodontitis: a randomized, placebo-controlled clinical trial. , 2015, Journal of periodontology.

[4]  J. Nart,et al.  Short-term effects of 2% atorvastatin dentifrice as an adjunct to periodontal therapy: a randomized double-masked clinical trial. , 2015, Journal of periodontology.

[5]  X. Zhang,et al.  Simvastatin inhibits lipopolysaccharide-induced osteoclastogenesis and reduces alveolar bone loss in experimental periodontal disease. , 2014, Journal of periodontal research.

[6]  Awan,et al.  Simvastatin local drug delivery in smokers with chronic periodontitis: a randomized controlled clinical trial , 2013, BDJ.

[7]  L. D. de Souza,et al.  Atorvastatin Decreases Bone Loss, Inflammation and Oxidative Stress in Experimental Periodontitis , 2013, PloS one.

[8]  R. Ribeiro,et al.  Protective mechanisms of simvastatin in experimental periodontal disease. , 2013, Journal of periodontology.

[9]  A. Pradeep,et al.  Clinical efficacy of subgingivally delivered 1.2% atorvastatin in chronic periodontitis: a randomized controlled clinical trial. , 2013, Journal of periodontology.

[10]  A. Pradeep,et al.  Clinical efficacy of subgingivally delivered 1.2-mg simvastatin in the treatment of individuals with Class II furcation defects: a randomized controlled clinical trial. , 2012, Journal of periodontology.

[11]  M. Sandhu,et al.  A CLINICAL, RADIOLOGICAL AND IL-6 EVALUATION OF SUBGINGIVALLY DELIVERED SIMVASTATIN IN THE TREATMENT OF CHRONIC PERIODONTITIS , 2012 .

[12]  P. Eke,et al.  Prevalence of Periodontitis in Adults in the United States: 2009 and 2010 , 2012, Journal of dental research.

[13]  S. Elavarasu,et al.  Statins: A new era in local drug delivery , 2012, Journal of pharmacy & bioallied sciences.

[14]  L. Bracht,et al.  Topical anti‐inflammatory effect of hypocholesterolaemic drugs , 2011, The Journal of pharmacy and pharmacology.

[15]  J. Gamonal,et al.  Clinical attachment loss in Chilean adult population: First Chilean National Dental Examination Survey. , 2010, Journal of periodontology.

[16]  A. Pradeep,et al.  Clinical effect of subgingivally delivered simvastatin in the treatment of patients with chronic periodontitis: a randomized clinical trial. , 2010, Journal of periodontology.

[17]  Chang Liu,et al.  The Effect of Simvastatin on mRNA Expression of Transforming Growth Factor-β1, Bone Morphogenetic Protein-2 and Vascular Endothelial Growth Factor in Tooth Extraction Socket , 2009, International Journal of Oral Science.

[18]  M. CarlosCalvo,et al.  Efectos pleiotrópicos de las estatinas , 2008 .

[19]  K. Suomalainen,et al.  Statin use is associated with fewer periodontal lesions: A retrospective study , 2008, BMC oral health.

[20]  Carlos León-Céspedes,et al.  Efectos no hipolipemiantes de las estatinas , 2007 .

[21]  A. B. Martínez,et al.  Papel de la IL-6 y TNF-alfa en la enfermedad periodontal , 2006 .

[22]  T. Maeda,et al.  Statins and bone metabolism. , 2006, Oral diseases.

[23]  BartStaels,et al.  Acute Antiinflammatory Properties of Statins Involve Peroxisome Proliferator–Activated Receptor-α via Inhibition of the Protein Kinase C Signaling Pathway , 2006 .

[24]  P. Gómez-Fernández [Statins and beneficial effects]. , 2005, Medicina clinica.

[25]  P. Nachtigal,et al.  The changes in the endothelial expression of cell adhesion molecules and iNOS in the vessel wall after the short‐term administration of simvastatin in rabbit model of atherosclerosis , 2005, The Journal of pharmacy and pharmacology.

[26]  H. Yazawa,et al.  Simvastatin promotes cell metabolism, proliferation, and osteoblastic differentiation in human periodontal ligament cells. , 2005, Journal of periodontology.

[27]  T. Maeda,et al.  Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. , 2003, Endocrinology.

[28]  A. M. Lefer,et al.  A new HMG‐CoA reductase inhibitor, rosuvastatin, exerts anti‐inflammatory effects on the microvascular endothelium: the role of mevalonic acid , 2001, British journal of pharmacology.

[29]  T. Komori,et al.  Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. , 2000, Endocrine reviews.

[30]  Ross R. Muth,et al.  Biodegradable polymers for use in surgery—polyglycolic/poly(actic acid) homo- and copolymers: 1 , 1979 .

[31]  D. Erdogan,et al.  Assessment of vascular endothelial growth factor and matrix metalloproteinase-9 in the periodontium of rats treated with atorvastatin. , 2014, Journal of periodontology.

[32]  A. Pradeep,et al.  Efficacy of subgingivally delivered simvastatin in the treatment of patients with type 2 diabetes and chronic periodontitis: a randomized double-masked controlled clinical trial. , 2013, Journal of periodontology.